Search Patents
  • Polypeptide comprising a knottin protein moiety
    Publication number: 20100267610
    Abstract: A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein.
    Type: Application
    Filed: February 18, 2008
    Publication date: October 21, 2010
    Applicant: BIONTECH AG
    Inventors: Michael Blind, Harald Kolmar
  • Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
    Publication number: 20190062762
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Application
    Filed: September 27, 2018
    Publication date: February 28, 2019
    Applicant: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Identification of tumor-associated markers for diagnosis and therapy
    Patent number: 10253373
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 9, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Compositions and methods for diagnosis and treatment of cancer
    Patent number: 10370433
    Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Biontech AG
    Inventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 9476055
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: October 25, 2016
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Silke Holtkamp, Özlem Türeci, Sebastian Kreiter
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 10106800
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 23, 2018
    Assignee: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer
    Patent number: 9175088
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: November 3, 2015
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Recombinant Vaccines and Use Thereof
    Publication number: 20180177885
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • RECOMBINANT VACCINES AND USE THEREOF
    Publication number: 20140134201
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 15, 2014
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Stabilised formulations of RNA
    Patent number: 10626400
    Abstract: The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: April 21, 2020
    Assignee: BioNTech AG
    Inventor: Steve Pascolo
  • Particles comprising single stranded RNA and double stranded RNA for immunomodulation
    Patent number: 10172960
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 8, 2019
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Particles comprising single stranded RNA and double stranded RNA for immunomodulation
    Patent number: 9636414
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 2, 2017
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • PREDICTING IMMUNOGENICITY OF T CELL EPITOPES
    Publication number: 20160125129
    Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 5, 2016
    Applicants: BioNTech AG, TROM
    Inventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
  • Recombinant vaccines and use thereof
    Patent number: 8637006
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 28, 2014
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Recombinant vaccines and use thereof
    Patent number: 8178653
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the transmembrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: May 15, 2012
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 9194004
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: November 24, 2015
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
    Patent number: 9061007
    Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 23, 2015
    Assignees: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 10302647
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 28, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Use of FLT3 ligand for enhancing immune responses in RNA immunization
    Patent number: 9486519
    Abstract: The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: November 8, 2016
    Assignees: BioNTech AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Sebastian Kreiter, Abderraouf Selmi
  • Tumor antigens for determining cancer therapy
    Patent number: 10188712
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 29, 2019
    Assignees: BIONTECH AG, TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
Narrow Results

Filter by US Classification